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Here, we show a strategy for high-through-
put antibody-based tissue profiling with the aim
to create an atlas of protein expression patterns
in normal human tissues and cancer tissues rep-
resenting the 20 most prevalent cancer types. A
set of standardized tissue microarrays (TMAs)
was produced to allow for rapid screening of a
multitude of different cells and tissues using
immunohistochemistry. Eight TMA blocks were
produced containing 48 different normal human
tissues in triplicate and cancer tissue from 216
individually different tumors in duplicate. Sec-
tions from these blocks were immuno-
histochemically stained using five commercial
and five in-house generated antibodies. Digital
images for annotation of expression profiles
were generated using a semiautomated
approach. Five hundred seventy-six images and
annotation data corresponding to a total of 30
Gbytes of data were collected for each antibody.
The data presented here suggest that antibody-
based profiling of protein expression in tissues
can be used as a valuable tool in clinical
proteomics.
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Introduction
The completion of the human genome
sequence and recent development of high-
throughput technologies have set the stage for a
clinical proteomics approach to analyze protein
expression patterns on a genome-wide scale.
The correlation between genotype and pheno-
type is poorly understood and presents a critical
challenge to functionally explore mechanisms
underlying normal development and disease.
The phenotypical appearance as seen in a tissue
section is evidently based on the pattern of
expressed proteins within a cell as well as com-
position of the surrounding microenvironment.
Microscopical evaluation of a tissue section
taken from an excised tumor remains the
golden standard for determining a diagnosis of
cancer, although immunohistochemistry has
provided additional support in cancer diagnos-
tics (1). In addition to determining expressed
proteins, analysis of genomic DNA and tran-
scribed genes add important information to the
histological features detected in the microscope.
Immunohistochemistry provides a power-
ful tool for visualization of protein expression
in tissues and cells. Immunohistochemistry
has played an important role in clinical
medicine as well as in basic research for defin-
ing different immunophenotypes present in
tissues (2). Major advancements in both basic
knowledge and refinement of diagnostics have
been made in the hematological field (3,4) and
an increasingly important role in detection of
different immunophenotypes is apparent in
solid tumors (5). Immunohistochemistry has,
in addition, been important to study more gen-
eral features, for example, proliferation and
differentiation, and also been required to dis-
close otherwise invisible cell populations such
as epidermal p53 clones (6). One important
objective for clinical proteomics is to generate
a protein atlas displaying expression and
localization patterns of proteins in all or most
human tissues and organs (7). Such a protein
atlas would function as a general knowledge
base with regard to the structural and tempo-
ral expression of the human proteins in vari-
ous cells and tissues. Furthermore, such a
database would also ultimately facilitate fur-
ther studies to explore the biochemical func-
tion of the corresponding proteins.
To allow for such a proteomics strategy, it is
important to develop high-throughput ways
to generate and use specific antibodies that
can be used as an immunohistochemical tool
for analysis of biopsies from human patients.
Agaton et al. showed recently that with bioin-
formatic selection of protein epitope signature
tags (PrESTs), it is possible to generate highly
specific antibodies in a high-throughput man-
ner as exemplified by a pilot study using the
genes of human chromosome 21 (8). Protein
fragments of the size 100–150 amino acid
residues were expressed and purified from
recombinant bacterial hosts and used to gen-
erate polyclonal antibodies. These antibodies
were affinity purified using the PrEST as
ligand (9), and the purified antibodies were
subsequently used for immunohistochemistry.
However, to allow for a comprehensive pro-
tein atlas covering most tissues and organs of
the human body, a more systematic approach
is needed for the immunohistochemistry to be
able to analyze many tissues in parallel. Here,
we describe the use of tissue microarray
(TMA) for such high-throughput antibody-
based tissue profiling. Immunohistochemistry
combined with TMA technology presents an
exceptional strategy for high-throughput anal-
ysis of protein expression in various tissues
and cells (7,10). The use of multiple biopsies or
curettages in a single paraffin block has been
used in surgical pathology procedures for sev-
eral decades. Although several papers have
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been published describing improvements of
methodology and usefulness in immunohis-
tochemistry (11–13), multitissue blocks did 
not become a powerful tool in research prior
to important standardization described by
Kononen and coworkers (14).
Here, we show that high-throughput analy-
sis of protein expression can be performed with
a standard set of TMAs representing both
normal and cancer tissues. The TMA technology
used in this study provides an automated array-
based high-throughput technique in which as
many as 1000 paraffin-embedded tissue sam-
ples can be brought into one paraffin block in
an array format. The diameter of the tissue
sample cores is small, here 1.0-mm diameter, to
prevent loss of valuable and unique tissues.
Using this strategy, we were able to generate
576 standard digital immunohistological images
for every antibody studied. This approach is
possibly to scale-up for whole proteome efforts
in which a large number of protein profiles are
generated by analyzing these tissue arrays.
Materials and Methods
Antibodies
Five commercially available antibodies,
with well-known staining properties, used
in routine diagnostic immunohistochemistry
were selected (Table 1). These antibodies were
chosen to represent different staining patterns
in human tissues including various subcellular
compartments, that is, nucleic (Cyclin A),
membranous (HER-2 and CD 34), and cyto-
plasmic (Keratin 14, GFAP).
The generation of affinity-purified antibod-
ies was performed essentially as previously
described (8). In brief, PrESTs corresponding
to a size of 100–150 residues were defined
using bioinformatic tools with the human
genome sequence as template (Ensembl
database, http://www.ensembl.org/). Follow-
ing RT-PCR and cloning, recombinant proteins
were produced and purified for immuniza-
tion. Polyclonal antisera were subsequently
affinity purified (9) and tested for specificity
and sensitivity using PrEST arrays prior to
immunohistochemical staining. In the present
study, five such PrEST antibodies were used
(Table 1). The PrEST antibodies included a few
antibodies recognizing proteins for which
there has been previously described expres-
sion patterns, for example, K230002 recogniz-
ing a zinc finger protein with probable nuclear
localization; K230003 recognizing a G protein
coupled receptor-associated sorting protein
(GASP) with possible membranous local-
ization; K230008 recognizing polyadenylate
binding protein 5 with possible cytoplasmic
localization; and K230009 recognizing dys-
kerin with expected nucleolar localization. For
the antibody K230011, there was no description.
Tissue Microarrays
Tissue and Tissue Processing
In total, 576 paraffin cores containing
human tissues were analyzed for each anti-
body. All tissues used as donor blocks for
TMA production were selected from the
archives at the Department of Pathology, Uni-
versity Hospital, Uppsala, in agreement with
approval from the local ethical committee.
Corresponding tissue sections were examined
to determine diagnosis and to select represen-
tative areas in donor blocks. Normal tissue
was defined as microscopically normal (non-
neoplastic) and was most often selected from
specimens collected from the vicinity of surgi-
cally removed tumors. Cancer tissue was
reviewed for diagnosis and classification. All
tissues were formalin fixated, paraffin embed-
ded, and sectioned for diagnostic purposes.
TMA Production
The TMA production was performed essen-
tially as earlier described (14,15). Briefly, a hole
was made in the recipient TMA block. A
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cylindrical core tissue sample from the donor
block was acquired and deposited in the recip-
ient TMA block. This was repeated in an auto-
mated tissue arrayer from Beecher Instrument
(ATA-27, Beecher Instruments, Sun Prairie,
CA) until a complete TMA design was pro-
duced. TMA recipient blocks were baked at
42°C for 2 h prior to sectioning.
TMA Design
The design of TMAs was emphasized on
obtaining samples from a large range of rep-
resentative normal tissues. Selection was lim-
ited to include only tissues from which
enough material could be taken to allow for a
large number of sample biopsies to be sent to
pathology for diagnosis. The other main focus
was to include representative cancer tissues.
We chose to include 20 of the most common
cancer types that affect humans. For 17 of
these cancer types, we included 12 individu-
ally different tumors. In total, eight different
designs of TMA blocks containing 72 cores
each of tissue with 1-mm diameter were pro-
duced. The spacing between each core center is
2 mm in both x- and y-axis. Two of these TMAs
included normal tissues (Table 2) and the
remaining 6 TMAs contained cancer tissue
from 20 different types of cancer (Table 3). From
17 of these cancer types, 12 individually differ-
ent tumors were sampled and from the remain-
ing 3 tumor types, 4 individually different
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Table 2 
All Utilized Normal Tissues 
Normal tissue










Fallopian tube Smooth muscle
Gall bladder Soft tissue 1




Lateral ventricle Thyroid gland
Lower stomach Tonsil
Liver Upper respiratory tract
Lung Upper stomach
Lymph node Urinary bladder
Oral mucosa Uterine cervix
Ovary Vagina
Pancreas Vulval-anal skin
Triplicate samples were collected from each normal
tissue and used as templates for the two normal
tissue microarray blocks.
Table 3 
All Cancer Tissues Including the Number 
of Individual Tumors Used 





















Duplicate samples were collected from each indi-
vidual tumor and used as templates for the six cancer
tissue microarrays.
Clinical Proteomics ________________________________________________________________ Volume 1, 2004
290 _______________________________________________________________________________ Kampf et al.
tumors were sampled. For normal tissues, trip-
licate samples from different individuals were
used and from cancer tissues, duplicates from
the same tumor were used (schematically
shown in Fig. 1). Four-micrometer thick sec-
tions were cut and two such sections were
placed on each glass slide.
Immunohistochemistry
Five commercially available antibodies and
five PrEST antibodies were selected for this
pilot study (Table 1). For the set of commer-
cial antibodies, manufacturers’ recommenda-
tions were used for antigen retrieval and
concentration of primary antibody. For the
PrEST antibodies, a test strategy was used to
determine methods of antigen retrieval and
antibody concentration. Slides containing var-
ious tissues were used to test different modes
of retrieval and concentration in order to
obtain a final protocol for immunohistochem-
ical staining. The immunohistochemical stain-
ing was performed as previously described
(16) using a system for automated immuno-
histochemistry (Autostainer, DakoCytomation,
Glostrup, Denmark). To test for specific bind-
ing, we mixed primary antibodies with a dilu-
tion series of respective PrEST antigen prior to
incubation of tissue sections. The adsorption
tests resulted in quenching of immunoreactiv-
ity. When primary antibodies were adsorbed
with 25 µg/mL, there was no detectable spe-
cific immunoreactivity.
Digital Imaging of the Tissue Cores
All immunohistochemically stained sections
from the eight different TMAs were scanned
using two automated slide-scanning systems,
the ACIS II (ChromaVision, San Juan Capistrano,
CA) and the ScanScope T2 (Aperion Technolo-
gies, Vista, CA). For each antibody, 576 digital
images were generated to represent the total
content of the eight TMAs. Scanning was per-
formed at 20 magnification. Digital images
were separated and extracted as individual
TIFF files for storage of original data. The size
of each TIFF image is approx 50 Mbytes,
depending on how close to the core the image
separation has occurred, that is, the amount of
white space around the core. Each TMA will
generate 3.6 Gbytes (72  50) of data; that is,
each antibody staining (eight TMAs) will gen-
erate approx 30 Gbytes of images excluding 
the database with annotation data. The high-
resolution TIFF images are stored on digital
tapes but the JPEG images and the database are
on-line, enabling instant access.
Scoring of Protein Expression
The annotation software was developed to
allow for a basic and rapid evaluation of
immunoreactivity in a broad spectrum of dif-
ferent tissues and cells. The annotation tool
software was developed to run on any stan-
dard desktop PC (Windows and Macintosh
operating systems) using an ordinary Web
browser interface. To handle the images in a
Web-based annotation system, we compressed
the individual images from TIFF format into
JPEG format. Parameters that were annotated
included overall staining, congruity in staining
between triplicate/duplicate samples, and reli-
ability of immunohistochemical staining, as
well as staining intensity, fraction of immunore-
active cells, pattern, and localization of
immunoreactivity (nuclear, cytoplasmic, or cell
membranous). A text box was also included for
comments.
Results
Design of TMAs Representing 
Normal Tissues
Two TMA blocks with 72 cores each were
designed containing normal tissues represent-
ing a broad spectrum of human organs and
tissues (Table 2). In all, 48 different tissues
were selected to represent the majority of
organs and tissues in the human body.
Selection of normal tissues was further based
Volume 1, 2004 ________________________________________________________________ Clinical Proteomics
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Fig. 1. Figure illustrating tissue microarray (TMA) design.The two normal TMAs containing 144 cores placed 
on one glass slide is shown (left). A schematic example of two cancer TMAs containing 144 cores from six
different types of cancer is shown (right).
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on the availability in pathology archives in
order to secure a constant design for screen-
ing on a genome-wide scale. Consequently,
certain specialized tissues, for example, spinal
chord, ear, and eye tissues, were omitted. To
avoid loss of data from individual differences
in expression patterns or technical failures, we
used triplicate samples. These samples were
selected from three different individuals and,
when applicable, both sexes were represented.
Design of TMAs Representing Cancerous
Tissues
Six TMA blocks with 72 cores each were
designed containing cancerous tissues repre-
senting the most common forms of cancers. As
heterogeneity is a hallmark of cancer, we
chose to include several tumors from each
tumor type in order to accomplish an accept-
able representation of tumor type. From 17
tumor types, we selected tumors from 12 dif-
ferent patients and from 3 tumor types, we
selected 4 individually different tumors (Table
3). Because we had a fairly large number of
tumors in each category, a duplicate sample
from each tumor was found sufficient to avoid
loss of data. One example of two cancer TMA
designs on a slide is shown in Fig. 2.
Production of the TMAs
Altogether, eight different types of TMA
blocks were produced with two TMAs corre-
sponding to normal tissues and six TMAs cor-
responding to the cancerous tissues. Each
TMA block allowed for cutting of approx 250
sections with a thickness of 4 m. In total,
5760 cores were sectioned and immunohisto-
chemically stained. From the expected 5760
cores stained and scanned, 231 cores were
missing (4%). Four hundred of the cores were
not representative, that is, did not include
selected normal tissue type or failed to include
selected cancer cells. The remaining 5129
stained spots were used as templates for eval-
uation and annotation. After exclusion of
missing images and nonrepresentative images,
89% of theoretically possible tissues were
available for analysis.
Analysis of the TMAs With Commercial
Antibodies
Five commercial antibodies were selected to
represent different expression patterns found
in tissues, that is, Cyclin A (proliferation in
cancer); HER-2 (HER-2 receptor positive breast
cancer); blood vessels (CD 34); brain tissue
(GFAP); and basal cells in squamous epithelia
(Keratin 14). The selection of antibodies was
furthermore based on different subcellular
compartments, including nucleus (Cyclin A),
cell membrane (HER-2 and CD 34), and cyto-
plasm (GFAP and Keratin 14). Immunohisto-
chemical staining of TMAs using the selected
commercial antibodies produced protein
expression patterns in accordance with earlier
experience and published data. In general,
immunohistochemical staining produced pat-
terns with low background and high speci-
ficity. Some examples are shown in Fig. 3.
Confirmation of expected staining pattern
included the following: (1) Clear staining of
vascular structures was evident using the anti-
CD34 antibody; (2) cyclin A immunoreactivity
coincided with what was expected for a
marker of a specific cell cycle phase in cancer
cells as well as certain normal proliferating tis-
sues; (3) the HER-2 antibody showed a clear
membranous staining pattern in a subset of
breast and other adenocarcinomas; (4) GFAP
staining was exclusively found in brain tissue
and malignant gliomas; and (5) Keratin 14
staining showed cytoplasmic immunoreactiv-
ity in epithelial structures known to express
Keratin 14.
Analysis of the TMAs With PrEST
Antibodies
Five PrEST-specific antibodies were also
analyzed in the same manner to show that an
antibody-based proteomics approach can be
Volume 1, 2004 ________________________________________________________________ Clinical Proteomics
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Fig. 2. Image showing immunohistochemically stained
tissue microarrays (TMAs). The figure shows an im-
munostained glass slide containing tissue sections from
two cancer TMAs stained with an in-house generated
antibody.
immunoreactivity in luminal lining of tubules
in the kidney, and a clear vascular pattern in
the spleen. Colorectal adenocarcinomas also
showed a widespread positivity along luminal
surfaces. The antibody generated toward
polyadenylate binding protein 5, K230008,
showed a strong positive staining in maturing
germinal cells of the testes and cells in the cere-
bellum, including Purkinje cells, whereas
cancer tissues only showed a weak cytoplas-
mic staining pattern. The PrEST antibody
K230009 generated toward dyskerin (nucleolar
protein NAP57) showed a clear immunoreac-
tivity in the nucleoli of most cells, especially
evident in cells such as keratinocytes, Purkinje
cells, and several cancer cells. For the K230011
antibody, generated toward a protein for which
there is no description, a positive staining pat-
tern was found in immature germinal cells of
the testes, molecular layer in cerebellum, and
outer membrane of proximal tubules of the
kidney. In cases where bioinformatics data on
gene/protein expression were available, the
outcome of the immunohistochemical staining
using PrEST antibodies on TMAs was compat-
ible with specific binding of the respective anti-
body. Adsorption with corresponding PrEST
protein prior to incubation of primary anti-
body abolished specific immunoreactivity in
all cases.
Digital Imaging of the Tissue Cores
Individual images of all 576 (72 cores 
eight TMAs) immunostained cores from 
the TMAs were extracted and stored in a
database. One slide containing two TMAs
(two TMAs  72 cores) was scanned and
stored as an original large TIFF file represent-
ing 144 cores. This image was divided using
image-extraction software into 144 separate
TIFF images, each representing one individ-
ual core. JPEG images were subsequently gen-
erated in several resolutions to enable
Web-based viewing and annotation. A brief
text annotation was made by a pathologist
used to generate the antibodies used to analyze
the tissues in the produced TMAs. Examples of
the immunohistochemical pattern of the PrEST
antibodies are shown in Fig. 4; expression pat-
terns are shown in normal tissues (Fig. 4A)
and cancer tissues (Fig. 4B). PrEST antibody
K230002, generated toward zinc finger protein
183, displayed a prevalent nuclear immunore-
activity in normal as well as cancerous cells,
with enhanced cytoplasmic immunoreactiv-
ity in Leydig cells of the testes and cells in
proximal tubules of normal kidney. The
K230003 antibody generated toward GASP
showed a distinctly different expression pat-
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Fig. 4. (A) Examples of normal tissues stained with the in-house-generated protein epitope signature tag
(PrEST) antibodies. Images shown from top to bottom include normal tissues from placenta, testes, cerebel-
lum, kidney, and spleen. Immunoreactivity for HPRK230002, HPRK230003, HPRK230008, HPRK230009, and
HPRK230011 antibodies are shown from left to right. Note the low background staining and clear differences
in staining patterns in the different tissues. (B) Examples of cancer tissues stained with the same antibodies
as in A. Cancer tissues shown include, from top to bottom: prostate carcinoma, colorectal carcinoma, and two
different cases of malignant glioma. Parallel sections from the same tissue microarray blocks were used to facil-
itate a comparison of the results from the different antibodies used.
and the following parameters were scored:
overall staining (negative or positive); con-
gruity (congruent or conflict); reliability
(distinct, probable, or uncertain); and, for
tissue-specific cells, intensity (strong, moder-
ate, weak, or negative); fraction of positive
cells (>75%, 25–75%, <25% or rare cells); stain-
ing pattern (homogenous or heterogeneous);
and localization (nuclear, cytoplasmic, mem-
branous, and/or extracellular). All data were
saved together with the corresponding
images in a database.
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Discussion
In this paper, we describe a strategy based
on antibody proteomics including TMAs 
to analyze protein expression patterns in 
a large number of normal and neoplastic
human tissues. The strategy has been to
develop a scalable system that can be used
on a whole proteome scale using tens of
thousands of specific antibodies. Each anti-
body will generate 576 high-resolution
images corresponding to normal and cancer
tissues. In this manner, a protein atlas for
tissue expression and localization will be
built up for each protein with an available
specific antibody. Here, we show that both
commercial antibodies and affinity-purified
polyclonal antibodies can be used to gener-
ate the data for the protein atlas.
The success for immunohistochemistry in a
clinical proteomics setting relies on the qual-
ity of antibodies and tissues used (7,17). We 
have chosen commercially available poly-
clonal and monoclonal antibodies with well-
known expected staining patterns as
examples, as well as antibodies generated
toward unique recombinant protein fragments
based on the human genome sequence (8).
Commercial antibodies were chosen to repre-
sent different subcellular localization patterns
and used as control for immunostaining. To
optimize protocols for immunostaining with
PrEST antibodies, a series of tests including
different modes of antigen retrieval (18) and
different concentrations of primary antibody
was performed prior to staining of the eight
TMAs. In cases where expression data were
available, staining patterns with PrEST antibod-
ies were consistent with a specific immunore-
activity for the given protein. For proteins
with unknown expression patterns, there 
Fig. 4. (continued)
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is no given true result; however, patterns of
immunoreactivity were evaluated by certified
pathologists, and adsorption with PrEST antigen
prior to immunostaining quenched the pattern
of immunoreactivity as expected for a specific
immunostaining.
Antibody-based tissue profiling allows a
streamlined approach for generating expres-
sion data, both for normal and disease tissue.
Our strategy for selection of tissues included
eight different TMA designs. The chosen strat-
egy, which includes 48 different samples of
normal human tissues in triplicate and dupli-
cate samples from 216 individually different
malignant tumors representing the 20 most
common forms of human cancer, provides a
first attempt to screen for different protein
expression patterns. As exemplified here for
cancer, it is possible to generate data on many
different individual patients to evaluate het-
erogeneity of tissue profiles. It is of course
possible to also include the analysis of other
clinically important diseases as long as clini-
cal material can be obtained in sufficient
amounts. Degenerative diseases, cardiovascu-
lar and metabolic diseases, infectious diseases,
and neurological disorders are examples of
disease that are suitable for antibody-based
tissue profiling as described here. Conse-
quently, it will also be important to extend the
analysis of protein expression in different
stages of development and in other species.
The fact that paraffin-embedded biosamples
can be used allows the inclusion of archive
material.
Scoring and annotation of protein expres-
sion was performed by a certified pathologist
to ensure a high quality of microscopical anal-
ysis and evaluation of immunoreactivity (19).
Complex tissue includes the existence of sev-
eral different cell types acting in concert to
execute normal organ function. A section from
a normal tissue will thus contain cells with
distinct and different phenotypes, including
differences in immunoreactivity for various
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antibodies. In certain tissues, only a minority
of present cells determines a specific function
of a defined tissue, for example, islet cells in
pancreatic tissue or glomerulus cells in kidney
tissue. For a meaningful assessment of protein
expression profiles, it is thus not possible to
merely measure intensity and extent of
immunoreactivity for a crude tissue core as
such. To acquire a sufficient resolution for
analysis, we have included the major cell
types that comprise a defined normal tissue,
for example, for cerebellum Purkinje cells,
cells of molecular layer and cells of granular
layer were analyzed separately and for uterus
endometrial gland cells, cytogenic stroma cells
and myometrial smooth muscle cells were
analyzed as different compartments. The level
of detail for a sufficient analysis can be
debated. For high-throughput tissue profiling,
time for annotation is an important and limit-
ing factor. However, a database containing
high-resolution images enables more in-depth
analysis as well as use of potential automated
image analysis tools in the future (20). Because
normal and cancer specimens were not patient
matched, it cannot be ruled out that differ-
ences in staining in part are from differences
in procurement and fixation rather than from
true biological differences. To compensate for
this to some extent, we included triplicate
samples from 3 different individuals as
normal tissues and 12 individually different
tumors for representation of different forms of
cancer. It is unlikely that differences from
treatment of tissues would cause systematic
errors.
To furthermore study protein expression in
defined cells, we have designed a TMA from
in vitro cultured cells (21) and patient cell sam-
ples (Stromberg, S. et al., unpublished data).
Such a cell-TMA facilitates a comparative anal-
ysis of transcription and protein expression
using immunohistochemistry combined with
image analysis and cDNA-array technologies.
In addition, cell-TMAs provide enhanced 
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possibilities to study hematological malignan-
cies for which there are readily available cell
aspirate samples as well as a multitude of
established cell lines for which data on genetic
background, transcription profiles, and protein
expression levels have been published. To a
lesser degree, cell-TMAs can also be used as
model systems for solid tumors and provide a
useful validation for selected antibodies.
Antibody-based tissue profiling is an impor-
tant complement to transcript profiling. As a
large amount of data is generated through the
use of microarray technologies, there is an
increasing demand to validate and compare
transcription profiles with protein expression
profiles in various normal as well as diseased
tissues. Subclassification of different cancer
types by gene expression analysis requires
optimal experimental design as well as sophis-
ticated management of data (22). Several exam-
ples exist in which differences in transcription
profiles have suggested that cancer types, as
defined through conventional histology,
include several subtypes with differences in
behavior, prognosis, and sensitivity to therapy,
for example, breast cancer (23,24). The pre-
sented strategy permits high-throughput tissue
profiling of specific antibodies on a genome-
wide scale and would provide an excellent
basis for validation of  up- and downregulated
genes. Furthermore, one could envision the
development of specific antibody panels as
tools for diagnostic and prognostic information
in given types of cancer. Immunohistochem-
istry allows for an enhanced understanding of
morphology as it adds important information
based on specific immunoreactivity in defined
cell populations. Today in clinical medicine,
analysis of immunohistochemical profiles as
well as mutation analysis and levels of tran-
scription can add important information
regarding prognosis and choice of treatment
for certain forms of cancer.
One of the advantages with the TMA ap-
proach for generating tissue profiles is the ease
of automation for scanning of the immuno-
histochemical cores using various commercial
software and hardware. Several different tech-
nologies for rapid scanning of glass slides
containing a tissue section have been devel-
oped (25). One major advantage of these tech-
niques is the generation of digital data
available for analysis. In a first pass, digital
images can be viewed and scored using con-
ventional Web-based tools and thus primary
data will be easily accessible. In order to
handle large file sizes using a Web-based inter-
face, our image files were compressed from
TIFF to JPEG files. Each image representing a
1-mm core could be reduced from approx 50
Mbytes to 1 Mbyte without detectable impair-
ment of image quality on an ordinary screen.
The reduced file sizes allows for rapid transi-
tion between images while performing annota-
tion. The compressed images also serve as a
basis for publishing primary data on the Web.
Although challenging, it is not impossible to
handle these large amounts of data.
In summary, we have shown that an anti-
body-based proteomics strategy can be used
to systematically explore clinical tissues using
a standardized set of TMAs. Using eight TMA
blocks with altogether 576 individual tissue
cores, it was possible to generate tissue
profiles including expression levels and local-
ization data, which are stored as digital im-
ages suitable for Web-based publishing. With
the approach described here, it should be pos-
sible to scale up to generate tissue profiles for
tens of thousands of antibodies. Thus, a com-
prehensive protein atlas for a large part of the
human proteome is possible if specific anti-
bodies can be generated within the framework
of various international efforts.
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